Swiss biopharmaceutical firm Debiopharm has started the dosing of the first patient in a Phase II proof-of-concept clinical trial of its antiviral alisporivir (Debio 025) for treating hospitalised Covid-19 patients.
On 14 December, the US Food and Drug Administration (FDA) approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab)…
French biopharmaceutical firm Genkyotex has reported positive data from the Phase I trial of its lead product candidate, setanaxib (GKT831), in healthy participants. A NOX1…
Swiss biopharmaceutical firm Debiopharm has started the dosing of the first patient in a Phase II proof-of-concept clinical trial of its antiviral alisporivir (Debio 025)…
Grifols is set to initiate a clinical trial in Spain to analyse a new Covid-19 drug, which can potentially offer…
Clinical-stage biopharma firm Seelos Therapeutics has dosed the first patients in its registrational 'Proof of Concept' study to evaluate SLS-002…
Dr Reddy’s Laboratories is all set to conduct a Phase III clinical trial of the Covid-19 vaccine, Sputnik V, after…
Cyxone has announced the screening of the first participant in the Phase II clinical trial to evaluate Rabeximod for treating…
On 7 January, Aldeyra Therapeutics announced top-line results from the run-in cohort of the Phase III trial evaluating its product 0.25% reproxalap for patients with dry eye syndrome (DES). The…
AzurRx BioPharma is working with CROs Rho and Linical for its Phase II and Phase IIb MS1819 trials, respectively, in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI), said CEO James…
Revitope Oncology will be open to CRO and CMO pitches in a couple of months for a Phase I trial after it selects its development candidate, said Chief Scientific Officer…
The UK government has banned Chinese technology firm Huawei from providing telecommunications equipment to the UK’s mobile 5G network from...
With Covid-19 delivering a great big slap in the face to ongoing and planned studies, the future of clinical trials as virtual has rapidly become...
Outsourcing is an important means for clinical trial sponsors to bring in outside expertise, from full-service clinical research organisations to smaller functional service providers. Here,...
REMD-377 topline results highlight the benefits of adjunct therapies in type 1 diabetes
REMD Biotherapeutics’ Phase II study of volagidemab has revealed improvements in glycemic control. The results revealed that volagidemab was associated with meaningful improvements in glycemic control, measured by haemoglobin A1c…